World Journal of Gastroenterology - Baishideng Publishing Group

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Ng ZC, Mehta PD, Brar AS, Sohal A, Goyal MK, Hatwal J, Batta A. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies. World J Diabetes 2026; 17(2): 113149 [PMID: 41696109 DOI: 10.4239/wjd.v17.i2.113149]
URL:	https://www.wjgnet.com/1007-9327/full/v17/i2/113149.htm

(48) (48) (0) (0) (0) (23) (2115) (25)

Number	Citing Articles
1	Ambrin Farizah Babu. Ketogenesis as a Metabolic Checkpoint in MASLD: Implications for Disease Progression and Therapy. Metabolites 2026; 16(9) doi: 10.3390/metabo16090659
2	Tessa Straatmijer, Midas Mulder. New therapeutic options for metabolic‐associated steatotic liver disease. British Journal of Clinical Pharmacology 2026; doi: 10.1002/bcp.70795
3	Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen. Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics. BMJ Open Gastroenterology 2026; 13(1) doi: 10.1136/bmjgast-2026-002343
4	Jing Zhou, Nenghan Zhang, Jiajun Li, Xiangqi Qin, Lingqi Kong, Liang Bai, Tuo Han. Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review. Exploration of Endocrine and Metabolic Diseases 2026; 3 doi: 10.37349/eemd.2026.101481
5	Marta Mallardo, Antonietta Messina, Vincenzo Monda, Marco La Marra, Antonietta Monda, Salvatore Allocca, Maria Casillo, Girolamo Di Maio, Pasquale Perrone, Aurora Daniele, Marcellino Monda, Giovanni Messina, Fiorenzo Moscatelli, Rita Polito. Lifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success. Nutrients 2026; 18(17) doi: 10.3390/nu18172748
6	Manjeet Kumar Goyal, Juniali Hatwal, Rupak Desai, Tanisha Sehgal, Akash Batta. Glycated hemoglobin and cardiovascular risk in diabetes mellitus: Evolving evidence beyond glycemic control. World Journal of Diabetes 2026; 17(6): 115820 doi: 10.4239/wjd.115820 Abstract(75) \| Core Tip(77) \| Full Article(HTML)(783) \| Full Article (PDF)-1625K(70) \| Full Article with Cover (PDF)-1973K(36) \| Full Article (XML)-136K(25) \| Audio-211K(5) \| Peer-Review Report-257K(30) \| Answering Reviewers-65K(32) \| Times Cited (1) \| Total Visits (1038) \| Open
7	Muneera AlTaweel, Mareyah Alshaikh Husain, Maram Rashid AlSubaiee, Ali Al Qarni, Ibraheem Aldossary. BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia. Current Medical Research and Opinion 2026; 42(5) doi: 10.1080/03007995.2026.2692167
8	Fernanda M. Martínez-Díaz, Elsie A. Jiménez-Cuevas, Mariana M. Ramírez-Mejía, Sarai Gómez-Camacho, Nahum Méndez-Sánchez. The interplay of insulin resistance, glycemic variability, and metabolic dysfunction-associated steatotic liver disease. Exploration of Digestive Diseases 2026; 5 doi: 10.37349/edd.2026.1005115
9	Mengyao Yan, Qian Xiang. Metabolic Syndrome: From Mechanisms to Therapeutic Interventions. MedComm 2026; 7(9) doi: 10.1002/mco2.70934
10	Ruizhe Ren, Siying Ren, Yihan Xu, Xiao Liang, Xiyang Wei. Non-coding RNA networks in metabolic dysfunction-associated steatotic liver disease: Mechanisms and therapeutic perspectives. Liver Research 2026; 10(2) doi: 10.1016/j.livres.2026.05.002
11	Oyinlola Oluwunmi Olaokun, Folakemi Damilola Olaokun. The Role of Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha in Type 2 Diabetes Mellitus and Neurodegenerative Diseases: A Systematic Review of Preclinical Evidence. Sci 2026; 8(8) doi: 10.3390/sci8080211
12	Manjeet Kumar Goyal, Juniali Hatwal, Rupak Desai, Tanisha Sehgal, Akash Batta. Do biomarkers matter? Cardiovascular risk stratification in Asian patients with metabolic dysfunction-associated steatotic liver disease in the era of fibrosis-centric assessment. World Journal of Gastroenterology 2026; 32(28): 117181 doi: 10.3748/wjg.117181 Abstract(70) \| Core Tip(55) \| Full Article(HTML)(303) \| Full Article (PDF)-570K(46) \| Full Article with Cover (PDF)-871K(63) \| Full Article (XML)-145K(27) \| Audio-1233K(8) \| Peer-Review Report-188K(23) \| Answering Reviewers-77K(25) \| Times Cited (2) \| Total Visits (563) \| Open
13	Lucy C. Taylor, Michael I. Adenawoola, Claire B. Wingfield, Maren K. Nadolski, David E. Stec. The Cardio-Renal-Hepatic Axis in MASLD. Role of BDNF, NGF, and Metabolic Cross-Talk. Current Hypertension Reports 2026; 28(1) doi: 10.1007/s11906-026-01388-1
14	Andong Li, Meiyu Wu, Yangke Yi, Yongtao He, Chongqing Tan, Xia Luo, Jun Zhang, Xiaomin Wan. Resmetirom for noncirrhotic metabolic dysfunction–associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany. Expert Review of Pharmacoeconomics & Outcomes Research 2026; doi: 10.1080/14737167.2026.2718421
15	Amedeo Lonardo, Ralf Weiskirchen. Interorgan Crosstalk in MASLD: A Narrative Review. Biomedicines 2026; 14(9) doi: 10.3390/biomedicines14091949
16	Berna Güleç, Ayşe Betül Bilen, Dilek Baykal. Dietary Fructose Intake, Metabolic Profile, and Liver Disease-Related Quality of Life in Adults with Obesity and MASLD: A Cross-Sectional Study. Metabolites 2026; 16(10) doi: 10.3390/metabo16100706
17	Ileana Pantea, Angela Repanovici, Hamza Islam. Tirzepatide in Metabolically Dysfunctional‐Associated Steatohepatitis (MASH): A Bibliometric and Evidence‐Based Review. Journal of Diabetes Research 2026; 2026(1) doi: 10.1155/jdr/1853763
18	Rishi Chowdhary, Manjeet Kumar Goyal, Megh Patel, Rahul Chowdhary, Kirti Arora, Varun Mehta, Akash Batta, Omesh Goyal, Ashita Rukmini Vuthaluru. Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction–associated steatotic liver disease. Frontiers in Epidemiology 2026; 6 doi: 10.3389/fepid.2026.1779600
19	Nebyu Yonas Shanka, Chavdar S. Pavlov, Taisiia A. Turankova, Temesgen Tesfaye Ajabo, Leul Mekonnen Nigatu, Biniyam Esayas Dana, Poorani Gurumallesh Prabu. Predicting Clinically Significant Portal Hypertension in MASLD Using Routine Ultrasound and Clinical Data: A Retrospective Cohort Study. BioMed Research International 2026; 2026(1) doi: 10.1155/bmri/1662756
20	Akash Batta, Arka De, Omesh Goyal, Aalam Sohal. Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions. Frontiers in Epidemiology 2026; 6 doi: 10.3389/fepid.2026.1893613
21	Mario Romeo, Claudio Basile, Andrea Imperatore, Giambattista Mozzi, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio, Alessandro Federico. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives. Cells 2026; 15(14) doi: 10.3390/cells15141292
22	Pooja Khatiwala, Joseph Ragan, Ashley Michael, Kyle Gleaves. Glycogenic Hepatopathy Mimicking Overlapping with Metabolic Dysfunction-Associated Steatotic Liver Disease in Newly Diagnosed Type 2 Diabetes: A Case Report. Sage Open Medical Case Reports 2026; 14 doi: 10.1177/2050313X261492855
23	Katerina Stefanaki, Dimitrios S. Karagiannakis, Maria Manolakopoulou, Stefania Magkou, Paraskevi Kazakou, Panagiota Zacharaki, Melpomeni Peppa, Evanthia Kassi, Theodora Psaltopoulou, Stavroula A. Paschou. Association of FIB‐4, APRI, and HellenicSCORE II With Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus. Journal of Diabetes Research 2026; 2026(1) doi: 10.1155/jdr/8029869